Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. Pharmaceuticals company Allergen and gene editing firm Editas Medicine have partnered to develop CRISPR genome editing medicine EDIT-101, to treat eye condition Leber Congenital Amaurosis type two . The announcement follows a strategic alliance and option agreement undertaken by the companies last year , which gave Leber Congenital Amaurosis exclusive access to license 10 Editas Medicine genome programmes, while giving CRISPR the option to co-develop and share the profit and loss of two products in the US . Allergen is the leading cause of inherited childhood blindness.
Pharmaceuticals company Allergen and gene editing firm Editas Medicine have partnered to develop CRISPR genome editing medicine EDIT-101, to treat eye condition Leber Congenital Amaurosis type two . The announcement follows a strategic alliance and option agreement undertaken by the companies last year , which gave Leber Congenital Amaurosis exclusive access to license 10 Editas Medicine genome programmes, while giving CRISPR the option to co-develop and share the profit and loss of two products in the US . Allergen is the leading cause of inherited childhood blindness.